Difference between revisions of "Venetoclax (Venclexta)"
Jump to navigation
Jump to search
m |
m |
||
Line 1: | Line 1: | ||
− | =Mechanism of action= | + | ==Mechanism of action== |
− | + | Bcl-2 inhibitor | |
− | =Preliminary results= | + | ==Preliminary results== |
+ | ===[[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)|Chronic lymphocytic leukemia]]=== | ||
# '''Abstract:''' Shuo Ma, John Francis Seymour, Mark C. Lanasa, Thomas J. Kipps, Jacqueline Claudia Barrientos, Matthew Steven Davids, Tanita Mason-Bright, Nikita Rudersdorf, Jianning Yang, Wijith Munasinghe, Ming Zhu, Elisa Cerri, Sari H. Enschede, Rod Humerickhouse, Andrew Warwick Roberts. ABT-199 (GDC-0199) combined with rituximab (R) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase 1b study. J Clin Oncol 32:5s, 2014 (suppl; abstr 7013) [http://meetinglibrary.asco.org/content/132375-144 link to abstract] | # '''Abstract:''' Shuo Ma, John Francis Seymour, Mark C. Lanasa, Thomas J. Kipps, Jacqueline Claudia Barrientos, Matthew Steven Davids, Tanita Mason-Bright, Nikita Rudersdorf, Jianning Yang, Wijith Munasinghe, Ming Zhu, Elisa Cerri, Sari H. Enschede, Rod Humerickhouse, Andrew Warwick Roberts. ABT-199 (GDC-0199) combined with rituximab (R) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase 1b study. J Clin Oncol 32:5s, 2014 (suppl; abstr 7013) [http://meetinglibrary.asco.org/content/132375-144 link to abstract] | ||
+ | |||
+ | [[Category:Drug index]] | ||
+ | [[Category:Chemotherapy]] | ||
+ | |||
+ | [[Category:Bcl-2 inhibitors]] | ||
+ | |||
+ | [[Category:Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications]] | ||
[[Category:Investigational]] | [[Category:Investigational]] |
Revision as of 00:28, 26 November 2014
Mechanism of action
Bcl-2 inhibitor
Preliminary results
Chronic lymphocytic leukemia
- Abstract: Shuo Ma, John Francis Seymour, Mark C. Lanasa, Thomas J. Kipps, Jacqueline Claudia Barrientos, Matthew Steven Davids, Tanita Mason-Bright, Nikita Rudersdorf, Jianning Yang, Wijith Munasinghe, Ming Zhu, Elisa Cerri, Sari H. Enschede, Rod Humerickhouse, Andrew Warwick Roberts. ABT-199 (GDC-0199) combined with rituximab (R) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase 1b study. J Clin Oncol 32:5s, 2014 (suppl; abstr 7013) link to abstract